Lab
Incyte Pathology, P.S.
Incyte Pathology, P.S. was paid $27.49M by Medicaid between Jan 2018 and Dec 2024, across 140 billing codes. Its largest line is 88305, Level IV - Surgical pathology, gross and microscopic examination — 25% of everything it billed.
33Billing provider infoINCYTE PATHOLOGY, P.S.
SPOKANE VALLEY, WA 99216
SPOKANE VALLEY, WA 99216
33aNPI1326086745assigned 06/04/2006
33bProvider typeClinical Medical Laboratory
28Total paid$27.49M
24GClaims921,229
24DCodes billed140
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Washington
Rank by total paid#7 of 76
Median peer was paid$90K
This provider vs. median304×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 86,024 | $3.18M | |
| 2019 | 91,971 | $3.35M | |
| 2020 | 108,354 | $4.43M | |
| 2021 | 188,135 | $5.71M | |
| 2022 | 179,595 | $4.94M | |
| 2023 | 168,879 | $3.64M | |
| 2024incomplete | 98,271 | $2.25M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 25% | 150,797 | 144,778 | $6.91M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 13% | 53,137 | 45,146 | $3.59M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 11% | 112,277 | 108,576 | $2.93M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 8.3% | 71,432 | 69,730 | $2.28M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 6.4% | 55,348 | 53,256 | $1.75M |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 6.3% | 55,167 | 52,993 | $1.75M |
| 88307 | 4.3% | 17,542 | 17,026 | $1.19M | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 3.9% | 35,560 | 34,210 | $1.08M |
| 87481 | 3.9% | 27,676 | 23,748 | $1.06M | |
| 87511 | 2.8% | 25,513 | 24,476 | $772K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.7% | 10,488 | 8,360 | $747K |
| 87653 | 1.7% | 14,369 | 14,081 | $459K |
128 more codes
| 88342 | 1.5% | 13,221 | $412K | |
| 88304 | 1.1% | 24,326 | $302K | |
| 88141 | <1% | 11,322 | $188K | |
| 87563 | <1% | 6,092 | $164K | |
| 87625 | <1% | 3,283 | $111K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 38,933 | $99K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 8,692 | $95K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 5,327 | $94K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 17,006 | $93K |
| 88142 | <1% | 4,424 | $93K | |
| 88312 | <1% | 1,418 | $84K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 26,934 | $84K |
| 86780 | <1% | 6,894 | $72K | |
| 86850 | <1% | 7,699 | $60K | |
| 80053 | Comprehensive metabolic panel | <1% | 8,086 | $55K |
| 86762 | <1% | 4,698 | $53K | |
| 88341 | <1% | 649 | $51K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,270 | $51K |
| 84702 | <1% | 3,845 | $48K | |
| 86803 | <1% | 4,335 | $43K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,148 | $43K |
| 86003 | <1% | 378 | $42K | |
| 87340 | <1% | 5,109 | $39K | |
| 80061 | Lipid panel | <1% | 4,733 | $37K |
| 84144 | <1% | 2,079 | $35K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 4,900 | $24K |
| 88360 | <1% | 313 | $21K | |
| 82670 | <1% | 926 | $20K | |
| 83001 | <1% | 1,311 | $19K | |
| 87631 | <1% | 179 | $19K | |
| 84146 | <1% | 1,270 | $18K | |
| 87186 | <1% | 2,538 | $17K | |
| 88189 | <1% | 430 | $17K | |
| 87070 | <1% | 2,367 | $17K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 355 | $16K |
| 80074 | <1% | 440 | $15K | |
| 84439 | <1% | 2,589 | $15K | |
| 82950 | <1% | 3,895 | $15K | |
| 87529 | <1% | 266 | $14K | |
| 87077 | <1% | 2,109 | $13K | |
| 86900 | <1% | 4,903 | $11K | |
| 86901 | <1% | 4,796 | $11K | |
| 88377 | <1% | 31 | $11K | |
| 80050 | General health panel | <1% | 1,473 | $11K |
| 83002 | <1% | 740 | $11K | |
| 87088 | <1% | 1,725 | $10K | |
| 82951 | <1% | 945 | $9K | |
| 82627 | <1% | 537 | $9K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,162 | $9K |
| 88112 | <1% | 486 | $9K | |
| 82728 | <1% | 1,305 | $9K | |
| 84481 | <1% | 605 | $8K | |
| 87147 | <1% | 1,594 | $7K | |
| 82607 | <1% | 909 | $7K | |
| 88302 | <1% | 832 | $6K | |
| 88313 | <1% | 202 | $5K | |
| 88331 | <1% | 100 | $5K | |
| 81003 | <1% | 3,151 | $5K | |
| 82746 | <1% | 537 | $5K | |
| 84270 | <1% | 350 | $5K | |
| 86317 | <1% | 504 | $5K | |
| 84403 | <1% | 278 | $4K | |
| 86696 | <1% | 256 | $4K | |
| 82570 | <1% | 1,135 | $4K | |
| 86225 | <1% | 445 | $4K | |
| 86038 | <1% | 469 | $4K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 785 | $4K |
| 84153 | <1% | 377 | $4K | |
| 87205 | <1% | 1,027 | $4K | |
| 86364 | <1% | 219 | $3K | |
| 84466 | <1% | 344 | $3K | |
| 86703 | <1% | 286 | $3K | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 978 | $3K |
| 87081 | <1% | 580 | $3K | |
| 83540 | <1% | 676 | $3K | |
| 86695 | <1% | 249 | $3K | |
| 87075 | <1% | 352 | $3K | |
| 86258 | <1% | 153 | $3K | |
| 88311 | <1% | 293 | $3K | |
| 85027 | <1% | 579 | $3K | |
| 88300 | <1% | 896 | $2K | |
| 84550 | <1% | 658 | $2K | |
| 86140 | <1% | 593 | $2K | |
| 84156 | <1% | 750 | $2K | |
| 82785 | <1% | 144 | $2K | |
| 81001 | <1% | 896 | $2K | |
| 85651 | <1% | 683 | $2K | |
| 82952 | <1% | 624 | $2K | |
| 86376 | <1% | 217 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 105 | $2K |
| 83970 | <1% | 78 | $1K | |
| 83525 | <1% | 131 | $1K | |
| 82043 | <1% | 345 | $1K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 12 | $1K |
| 87634 | <1% | 13 | $815.70 | |
| 88173 | <1% | 12 | $805.26 | |
| 86769 | <1% | 18 | $674.08 | |
| 88321 | <1% | 13 | $669.50 | |
| 82565 | <1% | 145 | $653.69 | |
| 86800 | <1% | 70 | $653.49 | |
| 84460 | <1% | 139 | $639.47 | |
| 84450 | <1% | 139 | $625.04 | |
| 86431 | <1% | 173 | $606.76 | |
| 86704 | <1% | 73 | $603.89 | |
| 83735 | <1% | 139 | $571.01 | |
| 86200 | <1% | 55 | $480.86 | |
| 83516 | <1% | 14 | $480.00 | |
| 83690 | <1% | 90 | $473.59 | |
| 82533 | <1% | 32 | $346.80 | |
| 83655 | <1% | 30 | $343.79 | |
| 87184 | <1% | 42 | $295.48 | |
| 84520 | <1% | 87 | $294.89 | |
| 83880 | <1% | 15 | $281.12 | |
| 84436 | <1% | 166 | $272.04 | |
| 88346 | <1% | 13 | $267.14 | |
| 85097 | <1% | 14 | $261.14 | |
| 84479 | <1% | 142 | $204.68 | |
| 80076 | <1% | 47 | $202.60 | |
| 82040 | <1% | 69 | $188.98 | |
| 85018 | <1% | 76 | $151.07 | |
| 85014 | <1% | 75 | $148.96 | |
| 85610 | <1% | 79 | $122.84 | |
| 80164 | <1% | 20 | $118.33 | |
| 0753T | <1% | 2,502 | $96.18 | |
| 85007 | <1% | 40 | $95.54 | |
| 83550 | <1% | 15 | $89.20 | |
| 83615 | <1% | 17 | $73.19 | |
| 0752T | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGOLDBERG, LINDA (BUSINESS OFFICE MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Incyte Pathology, P.S. | Spokane Valley, WA | $159K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.